Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabirnetug in early Alzheimer's disease
NCT06335173Phase 2Active, not recruiting
- Sponsor
- Acumen Pharmaceuticals, Inc.
- Start
- Feb 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of sabirnetug in Alzheimer's disease (AD), sponsored by Acumen Pharmaceuticals, Inc.. Started Feb 2024; status: active, not recruiting.
02
Drugs
sabirnetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06335173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335173.